STAT

DECEMBER 6, 2023

This comes on the heels of news that Novo Nordisk halted a clinical trial to test Wegovy’s impact on renal function early because the results they were seeing were so strong. Medicare spending on people with advanced metabolic disease is sobering. Yet beneath the hype lies a real fear. That will be costly.

Diabetes 260

Diabetes Drug Pricing 260

European Pharmaceutical Review

MARCH 14, 2024

In recent months there have been important development in the kidney disease treatment space. Additionally, there have been notable clinical developments for the treatment of kidney disorders. What are the greatest challenges in treating kidney disease?

Diabetes 95

Diabetes Labelling Immunity Immunization 95

European Pharmaceutical Review

MARCH 14, 2024

In recent months there have been important development in the kidney disease treatment space. Additionally, there have been notable clinical developments for the treatment of kidney disorders. What are the greatest challenges in treating kidney disease?

Diabetes 95

Diabetes Labelling Immunity Immunization 95

Pharmacy Times

NOVEMBER 15, 2022

Dapagliflozin and standard of care found to slow the decline in kidney function and lower the incidence of kidney failure.

52

52

Pharmafile

NOVEMBER 6, 2023

AstraZeneca has announced results from the ZENITH-CKD phase 2b clinical trial for the combination of zibotentan with dapagliflozin for the treatment of patients with chronic kidney disease (CKD) and proteinuria.

64

64

European Pharmaceutical Review

JULY 26, 2023

The European Commission (EC) has approved Jardiance ® (empagliflozin) for adults with chronic kidney disease (CKD). We celebrate this significant milestone [for this new treatment option] in the field of chronic kidney disease,” commented Daniel Gallego, President of European Kidney Patients’ Federation.

Diabetes 93

Diabetes Labelling Hospitals 93

World Pharma News

DECEMBER 18, 2023

In a clinical trial of patients with chronic kidney disease, an experimental drug significantly reduced albuminuria - albumin in urine, a sign of kidney damage - for 50% of participants.

71

71

Pharma Times

JANUARY 27, 2023

Clinical study is researching patients with diabetes and advanced chronic kidney disease

Diabetes 108

Diabetes 108

Pharmaceutical Technology

MAY 17, 2023

Chinook Therapeutics and Ionis Pharmaceuticals have entered a partnership to develop an antisense oligonucleotide (ASO) therapy to treat a rare, severe chronic kidney disease. Antisense therapies are designed for destroying mRNA, reducing the amount of disease-causing protein.

98

98

European Pharmaceutical Review

OCTOBER 18, 2023

Ardelyx’s first-in-class oral treatment is indicated to reduce serum phosphorus in adults with chronic kidney disease ( CKD ) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant to phosphate binder therapy.

Adverse Reactions 111

Adverse Reactions Labelling 111

Express Pharma

JANUARY 17, 2024

Finerenone is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalisation for heart failure in adult patients with chronic kidney disease associated with type 2 diabetes mellitus.

Diabetes 98

Diabetes 98

Express Pharma

FEBRUARY 16, 2024

It should be noted that Jardiance is not recommended for the treatment of CKD in patients with polycystic kidney disease, or patients requiring or with a recent history of intravenous immunosuppressive therapy or greater than 45 mg of prednisone or equivalent for kidney disease.

Diabetes 59

Diabetes Hospitals 59

ALiEM - Pharm Pearls

FEBRUARY 16, 2024

An 86-year-old man with a past medical history of coronary artery disease, hypertension, hyperlipidemia, chronic kidney disease, COPD, choledocholithiasis requiring ERCP and sphincterotomy 2 years ago presented with five days of feeling unwell. View other cases from this Clinical Image Series on ALiEM.

Hospitals 158

Hospitals 158

European Pharmaceutical Review

NOVEMBER 7, 2022

Results from the EMPA-KIDNEY Phase III clinical trial announced at the American Society of Nephrology (ASN)’s Kidney Week 2022, demonstrated Jardiance ® (empagliflozin) reduced the risk of kidney disease progression or cardiovascular death by 28 percent versus placebo in adults with chronic kidney disease (CKD).

Diabetes 82

Diabetes 82

pharmaphorum

FEBRUARY 21, 2022

Bayer has claimed EU approval for Kerendia, its new drug for chronic kidney disease (CKD) in people with type 2 diabetes, as the company tries to build a role of the drug alongside rival therapies from AstraZeneca and Johnson & Johnson.

Diabetes 120

Diabetes 120

Pharmaceutical Technology

JANUARY 10, 2023

CinCor Pharma is focused on developing new treatments for chronic kidney disease and resistant and uncontrolled hypertension. It is currently in clinical development to treat hypertension and primary aldosteronism. AstraZeneca stated that the transaction would boost its cardiorenal pipeline by adding baxdrostat.

97

97

Pharmaceutical Technology

OCTOBER 27, 2023

DF-003 is under clinical development by Drug Farm and currently in Phase I for Chronic Kidney Disease (Chronic Renal Failure).

52

52

Pharmaceutical Technology

OCTOBER 27, 2023

DF-003 is under clinical development by Drug Farm and currently in Phase I for Chronic Kidney Disease (Chronic Renal Failure).

52

52

European Pharmaceutical Review

OCTOBER 16, 2023

billion, Novo Nordisk has agreed to acquire ocedurenone for uncontrolled hypertension with potential application in cardiovascular and kidney disease from KBP Biosciences. To date, the small molecule drug has been evaluated in nine clinical trials. In a deal of up to $1.3

Diabetes 59

Diabetes 59

PharmD Live

JUNE 13, 2022

Because of the insidious nature of chronic kidney disease, and because most people affected do not have symptoms until the condition becomes advanced, it is sometimes under-recognized by busy healthcare providers. Of these 37 million Americans, approximately 90% of them with chronic kidney disease don’t know they have it.

Diabetes 52

Diabetes Physician Offices Hospitals 52

Pharmacy Times

JANUARY 19, 2023

Data from a randomized clinical trial supports previous clinical findings on SGLT2 inhibitors and their ability to slow the progression of chronic kidney disease.

63

63

Express Pharma

APRIL 3, 2023

Dr N Ranganathan, Founder, Kibow Biotech and Pari CKDu Foundation, US announced a philanthropic collaboration with Tanker Foundation, Chennai and Centaur Pharmaceuticals, to explore potential novel treatment options for Chronic Kidney Disease of Unknown Etiology (CKDu) patients.

Diabetes 96

Diabetes 96

RX Note

SEPTEMBER 10, 2023

Definition CKD is defined by the presence of kidney damage or decreased kidney function for 3 or more months , irrespective of the cause. It is a state of progressive loss of kidney function, ultimately resulting in the need for renal replacement therapy (dialysis or transplantation). Renal function trajectory pattern.

Diabetes 52

Diabetes Dosage Communication 52

Pharmafile

JANUARY 9, 2023

AstraZeneca has announced that it is set to acquire the clinical-stage biopharmaceutical company CinCor in a deal worth up to $1.8bn. US-based CinCor focuses on the development of novel treatments for resistant and uncontrolled hypertension, as well as to treat chronic kidney disease. read more.

78

78

RX Note

SEPTEMBER 8, 2023

Acute Kidney Injury Acute kidney injury (AKI) refers to the abrupt decrease in kidney function , resulting in the retention of urea and other nitrogenous waste products and in the dysregulation of extracellular volume and electrolytes. This must occur in both kidneys in order to cause AKI.

Dosage 52

Dosage Diabetes Communication 52

LifeProNow

MAY 8, 2023

The approval of Farxiga in the US not only reinforces AstraZeneca’s commitment to reducing the burden of this complex and life-threatening disease, but will help patients across the full spectrum of heart failure lead healthier lives.”

Diabetes 130

Diabetes 130

RX Note

NOVEMBER 18, 2023

Contraindications: Uncontrolled hypertension, pure red cell aplasia (PRCA) secondary to any erythropoietin protein drugs and known hypersensitivity to any component of ESA Red Cell Transfusion When managing chronic anaemia, the benefits of red cell transfusions may outweigh the risks in patients in whom ESA therapy is ineffective (e.g.,

Adverse Reactions 40

Adverse Reactions 40

pharmaphorum

MARCH 3, 2022

The results of the EMPULSE trial showed that adults hospitalised for acute heart failure were 36% more likely to see an improvement on clinical measures – including all-cause mortality, frequency of heart failure events, time to first heart failure event, and symptoms – in the first 90 days after treatment started compared to placebo.

Labelling 98

Labelling Diabetes Hospitals 98

ALiEM - Pharm Pearls

DECEMBER 4, 2023

Metastatic calcinosis cutis occurs in patients with underlying disorders of calcium or phosphorus metabolism (and therefore abnormal calcium and phosphorus levels) and can also be associated with calcium deposition in blood vessels, lungs, kidneys, and intestines (1). Am J Kidney Dis. 2015 Jul;66(1):133-46. doi: 10.1053/j.ajkd.2015.01.034.

Hospitals 150

Hospitals Medical Schools Diabetes 150

Pharmaceutical Technology

MAY 23, 2023

The UK’s medicines and healthcare products regulatory agency (MHRA) has granted marketing authorisation for Akebia Therapeutics’ Vafseo (vadadustat) to treat symptomatic anaemia associated with chronic kidney disease (CKD) in adult patients on chronic maintenance dialysis.

Labelling 52

Labelling 52

Pharmaceutical Technology

OCTOBER 27, 2022

Bayer has received approval from Health Canada for finerenone as an adjunct to standard-of-care treatment for chronic kidney disease (CKD) and type 2 diabetes (T2D) in adult patients. Health Canada approval is based on the positive data from the Phase III FIDELIO-DKD and FIGARO-DKD clinical trials of Kerendia.

Diabetes 52

Diabetes Hospitals 52

Pharma Leaders

JUNE 27, 2023

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has provided a positive opinion recommending authorisation of GlaxoSmithKline’s (GSK) daprodustat for symptomatic anaemia linked to chronic kidney disease (CKD). CKD is characterised by gradual kidney function loss.

52

52

European Pharmaceutical Review

JUNE 13, 2023

Chinook Therapeutics has two late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease. Clinical data has shown atrasentan has demonstrated significant reductions in proteinuria. IgA nephropathy IgAN is a progressive, rare kidney disease. The post £2.5b

Immunity 52

Immunity Immunization 52

European Pharmaceutical Review

JANUARY 9, 2023

The deal also offers the possibility for baxdrostat (CIN-107) to be combined with Farxiga ( dapagliflozin ), helping to address cardiorenal diseases, where there is a high unmet medical need. In clinical trials, baxdrostat was observed to significantly lower aldosterone levels without affecting cortisol levels, across a wide range of doses.

89

89

European Pharmaceutical Review

MAY 8, 2023

A marketing authorisation for PRX-102 (pegunigalsidase alfa) , the first Poly(ethylene glycol) (PEG)ylated enzyme for Fabry disease, has been granted by the European Commission (EC). CHMP recommends first pegylated enzyme for Fabry disease… The PEGylated enzyme replacement therapy Chiesi Global Rare Diseases and Protalix BioTherapeutics, Inc.

83

83

Pharmaceutical Business Review

JANUARY 4, 2024

This therapy is designed for the treatment of multiple sclerosis (MS), a chronic neurodegenerative autoimmune disease. Kyverna is committed to further exploring KYV-101’s potential for additional indications and developing a pipeline of immunotherapies to address unmet medical needs in autoimmune diseases.

59

59

pharmaphorum

NOVEMBER 5, 2021

Tens of thousands of people with chronic kidney disease in England could be eligible for treatment with AstraZeneca’s SGLT2 inhibitor Forxiga, after NICE backed NHS use of the drug in draft recommendations. mg/mmol or more – both measures of kidney function. m2 and a urine albumin-to-creatinine ratio (uACR) of 22.6

Diabetes 91

Diabetes 91